NeuroSense Therapeutics Ltd NRSN
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if NRSN is a good fit for your portfolio.
News
-
NeuroSense and Genetika+ Initiate Precision Medicine Collaboration Beginning with Ongoing Phase 2 Clinical Trial in Alzheimer's Disease
-
NeuroSense Presents Positive Data Validating Phase 2b Topline Readout During Emerging Science Presentation at the American Academy of Neurology Annual Meeting
-
NeuroSense to Present PARADIGM Data at the American Academy of Neurology Annual Meeting April 16, 2024
-
NeuroSense Announces Pricing of $4.5 Million Registered Direct Offering and Concurrent Private Placement
-
NeuroSense Collaborates with Lonza to Identify Exosome-based Biomarkers, in order to Advance Neurodegenerative Disease Treatments and Diagnostics
-
NeuroSense Announces Year End 2023 Financial Results and Provides Business Update
-
NeuroSense Reports Additional Positive Results from its ALS Phase 2b PARADIGM Trial
-
NeuroSense Regains Compliance with NASDAQ Minimum Bid Price Rule
Trading Information
- Previous Close Price
- $1.26
- Day Range
- $1.17–1.29
- 52-Week Range
- $0.40–2.33
- Bid/Ask
- $1.23 / $1.32
- Market Cap
- $21.32 Mil
- Volume/Avg
- 42,146 / 307,724
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases, these diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease and Parkinson's disease, among others. Its product candidate, PrimeC, is a novel extended-release, or ER, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 16
- Website
- https://www.neurosense-tx.com
Valuation
|
Metric
|
NRSN
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
NRSN
|
|---|---|
Quick Ratio | 0.81 |
Current Ratio | 0.84 |
Interest Coverage | −1,040.64 |
Quick Ratio
NRSN
Profitability
|
Metric
|
NRSN
|
|---|---|
Return on Assets (Normalized) | −184.21% |
Return on Equity (Normalized) | −1,109.65% |
Return on Invested Capital (Normalized) | −991.55% |
Return on Assets
NRSN
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Smxqmsfgz | Psrm | $554.7 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Kgzhsmy | Dfhzbmt | $102.7 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Gbsgbdqz | Zbkwl | $97.8 Bil | |
MRNA
| Moderna Inc | Lcnxvghj | Lbxh | $41.3 Bil | |
ARGX
| argenx SE ADR | Krwlksfr | Ttq | $22.3 Bil | |
BNTX
| BioNTech SE ADR | Hgmhygvf | Wswg | $21.0 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Xbrsyjywp | Pwdrb | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Yxbqrnrz | Rnrfg | $15.4 Bil | |
RPRX
| Royalty Pharma PLC Class A | Jkkwpqxlf | Nfnybp | $12.5 Bil | |
INCY
| Incyte Corp | Jbhccssh | Yrgltx | $11.6 Bil |